Immunomedics regains CEA-Scan rights

Article

Monoclonal antibody developer Immunomedics has reacquired NorthAmerican marketing rights to its CEA-Scan agent from Pharmaciaof Sweden. Immunomedics, of Morris Plains, NJ, said Pharmaciahas changed its strategic direction and scaled back its cancersales

Monoclonal antibody developer Immunomedics has reacquired NorthAmerican marketing rights to its CEA-Scan agent from Pharmaciaof Sweden. Immunomedics, of Morris Plains, NJ, said Pharmaciahas changed its strategic direction and scaled back its cancersales force, and has agreed to return rights for the colorectalcancer imaging agent to Immunomedics as part of the restructuring.

Pharmacia won North American marketing rights to CEA-Scan afterits 1993 acquisition of Adria Laboratories, the product's initiallicensee. Mallinckrodt Medical has European marketing rights toCEA-Scan, which is under regulatory review in the U.S., Canadaand Europe.

In other Immunomedics news, the company said it recently filedan application with the European Medicines Evaluation Agency (EMEA)for approval to market LeukoScan, a technetium-labeled monoclonalantibody-based agent for the detection of osteomyelitis in longbones and diabetic foot ulcers. EMEA approval of LeukoScan willgive Immunomedics the go-ahead to market the product in all 15nations of the European Union.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.